Prescribing Trends and Associated Outcomes of Antiepileptic Drugs in US Nursing Homes Surrounding the COVID-19 Pandemic - Trial NCT06095284
Access comprehensive clinical trial information for NCT06095284 through Pure Global AI's free database. This phase not specified trial is sponsored by Virginia Commonwealth University and is currently Enrolling by invitation. The study focuses on Dementia. Target enrollment is 22500000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Virginia Commonwealth University
Timeline & Enrollment
N/A
Sep 01, 2022
Jun 30, 2027
Primary Outcome
Quarterly rate of use and mean dose of AEDs in US nursing homes
Summary
Since the National Partnership to Improve Dementia Care debuted in 2012, almost all
 long-stay psychoactive prescribing has been graded by CMS, which has correlated to decreased
 use. However, some national data suggest that while these psychoactive medications are being
 used less, prescriptions of mood-stabilizing antiepileptic drugs (AEDs) have increased.
 Unlike all other psychoactive medications, AEDs prescribed in nursing homes are not
 mandatorily reported to CMS or graded in a quality-measure.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06095284
Non-Device Trial